Accelerating Splicing Modulation Therapies for Neurodegeneration with the VoyagR Platform
Time: 11:00 am
day: Conference Day One
Details:
• Finalizing development of a lead candidate targeting HTT and PMS1 splicing with support from CIRM for IND-enabling studies in Huntington’s disease to accelerate clinical readiness and unlock therapeutic potential
• Accelerating preclinical development with refined single-molecule chemistry and new functional datasets to enhance compound validation and improve translational confidence in ReviR’s lead asset
• Expanding ReviR’s pipeline with additional splicing-modulation programs in spinal muscular atrophy and Charcot-Marie-Tooth disease to broaden therapeutic reach and address unmet needs in neurodegeneration
